Several studies have shown that the 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) receptor protein levels increase in response to 1,25-(OH)2D3. We have studied the mechanism of this regulation in both mouse fibroblasts and rat intestinal epithelial cells. Cell extracts and total RNA were prepared at varying times after addition of 1,25-(OH)2D3. The 1,25-(OH)2D3 receptor protein levels, measured using an immunoradiometric assay, rose significantly 2-3 h posttreatment and had risen 3-fold at 8 h. Concurrently, the 1,25-(OH)2D3 receptor mRNA content, measured using a ribonuclease protection assay, was not altered by 1,25-(OH)2D3 during this time. In cycloheximide-blocked cells, the administration of 1,25-(OH)2D3 markedly reduced the degradation rate of previously formed receptor. The 1,25-(OH)2D3 receptor protein half-life was determined as 4 h in the absence of 1,25-(OH)2D3 and increased to at least 8 h in the presence of 1,25-(OH)2D3. We also measured the 1,25-(OH)2D3 receptor mRNA levels in the duodena and kidney of vitamin D-deficient rats after a single 150-pmol injection of 1,25-(OH)2D3. Again, we found that 1,25-(OH)2D3 receptor mRNA levels were not changed in these tissues after 1,25-(OH)2D3 treatment. Therefore, the elevation of the 1,25-(OH)2D3 receptor protein following 1,25-(OH)2D3 administration is apparently the result of increased receptor protein lifetime and not increased transcription.
No takes yet. Share an insight, caveat, or question.
Wiese et al. (1992) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: